With immunodeficiencies and autoimmune diseases becoming more prevalent1-3 the healthcare system is in need of rapidly available and effective treatments. Grifols’ extensive scientific work in this area builds on our expertise in the treatment of immunodeficiencies through, for example, intravenous immunoglobulin (IVIg). We are striving to enhance treatment availability while expanding into potential additional indications.
We developed our first SCIg to treat primary immunodeficiencies4 and some secondary immunodeficiencies. It’s administered under the skin for a more convenient dosing option and faster infusion than intravenous administration, enhancing patients’ treatment alternatives.
We are advancing additional intravenous Ig products, manufactured using an innovative production process, for the treatment of primary immunodeficiencies and autoimmune diseases such as chronic immune thrombocytopenia (ITP), for which Grifols also provides a small-molecule treatment.
Grifols is extending its longtime expertise in Igs into disorders in which the immunodeficiency and low levels of Igs is a consequence of a disease (secondary immunodeficiency), such as some hematologic neoplasms like chronic lymphocytic leukemia (CLL). We believe our Ig treatments can improve quality of life for people living with this disease.
1 Meyts I, Bousfiha A, Duff C, et al. Primary immunodeficiencies: A decade of progress and a promising future. Front Immunol. 2021; 11:625753. doi:10.3389/fimmu.2020.625753
2 Quinn J, Modell V, Orange JS, et al. Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network. Allergy Asthma Clin Immunol. 2022; 18 (19). Doi: https://doi.org/10.1186/s13223-022-00662-6
3 Dinse GE, Parks CG, Weinberg CR, et al. Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol. 2020;72(6):1026-1035. doi: 10.1002/art.41214
4 Santamaria M, Neth O, Douglass JA, et al. A multi-center, open-label, single-arm trial to evaluate the efficacy, pharmacokinetics, and safety and tolerability of IGSC 20% in subjects with primary immunodeficiency. J Clin Immunol. 2022;42(3):512-513. doi:10.1007/s10875-021-01181-6
Patients are at the center of our far-ranging scientific research to develop therapeutic solutions to some of the world’s most pressing healthcare challenges.
